Spring Works Therapeutics (SWTX) PT Raised to $48 at Wedbush
- Wall Street comes off record highs ahead of big tech earnings
- Tesla (TSLA) Gains on Q2 Beat, Analysts Mostly Positive but Others Cautious
- China's Meituan (MPNGF) Plunges 17.6% to Push Hang Seng Index to 8-Month Lows as Heavy Selling Continues
- Raytheon (RTX) Gains on Beat-and-Raise, CEO Says Next War Will Be Fought in Cyber Space and Then Outer Space
- Dollar eases slightly with Fed in focus
Wedbush analyst David Nierengarten raised the price target on Spring Works Therapeutics (NASDAQ: SWTX) to $48.00 (from $45.00) while maintaining a Outperform rating.
You May Also Be Interested In
- SpringWorks Therapeutics Inc. (SWTX) Appoints Dr. James Cassidy as Chief Medical Officer
- First National Financial Corp. (FN:CN) (FNLIF) PT Lowered to Cdn$51 at Scotiabank
- Axis Bank Ltd. (AXSB:IN) PT Raised to INR900 at UBS
Create E-mail Alert Related CategoriesAnalyst PT Change
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!